GLPwatch

Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists.

Diabetes Obes Metab · 2022

Last updated 2026-05-28

In a UK study of 1,000 people, switching to injectable semaglutide led to improvements in blood sugar control and weight loss, regardless of prior GLP-1 drug use. However, those switching from dulaglutide or liraglutide saw smaller blood sugar reductions, and those switching from dulaglutide or exenatide experienced less weight loss, suggesting these drugs may have different strengths.

AI summary of the abstract below.

JournalDiabetes Obes Metab, 2022
Citations11
Relative citation ratio0.96
NIH percentile49
Molecules semaglutide
Conditions studied Type 2 Diabetes, Obesity

Abstract

The ABCD semaglutide audit was designed to capture the routine clinical outcomes of people commenced on semaglutide in the UK. Previous work showed differential reductions in HbA1c and weight dependent on previous glucagon-like peptide-1 receptor agonist (GLP-1RA) exposure. The analysis, in this research letter, shows that decreases in HbA1c and weight associated with semaglutide occur irrespective of previous GLP-1RA use. However, HbA1c reductions were less if switched from dulaglutide or liraglutide and weight changes were attenuated if switched from dulaglutide or exenatide, potentially suggesting differing potencies between GLP-1RAs. Dedicated studies with head-to-head comparisons are needed to confirm these findings.

Verbatim abstract via PubMed 35322528 ↗

Related research